INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 413m ago
HOUSE PTR13m ago
SEC 13F13m ago
ROBINHOOD CHAIN13m ago
SEC FORM 4/Grant or awardVerified data

Lizzul Paul F. reported ANAB

Chief Medical Officer · ANAPTYSBIO, INC · ANAPTYSBIO, INC — Stock Option (right to buy)

Side
A
Value
—
Shares
29.0K
Price
—
Executed
Jan 6, 2026
Disclosed
Jan 8, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 6 executedJan 8, 2026 disclosed

ANAB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ANAB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    MM
    Murphy Christopher M.Chief Financial Officer
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    25.8K sh
    		May 11, 2026May 13, 2026
    traded May 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    11.3K sh
    		Apr 27, 2026Apr 29, 2026
    traded Apr 27, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    11.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    2,321 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    2,321 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    9,200 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    9,200 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    194.9K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    194.9K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    379.6K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    379.6K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    305.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    305.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    133.4K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Grant or award
    		A—
    133.4K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    14
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Disposition to issuer
    		D—
    11.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    17
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$33K
    550 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$203K
    3,155 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$215K
    3,662 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    FD
    Faga DanielDirector, President, CEO
    ANABANAPTYSBIO, INC
    Open-market sale
    		SELL$164K
    2,592 sh
    		Mar 27, 2026Mar 27, 2026
    traded Mar 27, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001711462-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 6, 2026
    Published
    Jan 8, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Lizzul Paul F.
    Role
    Chief Medical Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ANAPTYSBIO, INC — Stock Option (right to buy)
    Ticker
    ANAB
    Shares
    29.0K
    Price per share
    $0
    Execution date (reported)
    Jan 6, 2026
    Owned after transaction
    29.0K shares
    Days from execution to publication
    2

    What this establishes

    Lizzul Paul F. filed this Form 4 reporting a grant or award of ANAB on Jan 6, 2026. It became public on Jan 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Lizzul Paul F.cik:0001711462
    Issuer
    ANAPTYSBIO, INCcik:0001370053

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.